These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 15269138)
41. Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs. Lasorsa A; Nardella MI; Rosato A; Mirabelli V; Caliandro R; Caliandro R; Natile G; Arnesano F J Am Chem Soc; 2019 Jul; 141(30):12109-12120. PubMed ID: 31283225 [TBL] [Abstract][Full Text] [Related]
42. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Liu JJ; Kim Y; Yan F; Ding Q; Ip V; Jong NN; Mercer JF; McKeage MJ Biochem Pharmacol; 2013 Jan; 85(2):207-15. PubMed ID: 23123662 [TBL] [Abstract][Full Text] [Related]
43. Copper transport systems are involved in multidrug resistance and drug transport. Furukawa T; Komatsu M; Ikeda R; Tsujikawa K; Akiyama S Curr Med Chem; 2008; 15(30):3268-78. PubMed ID: 19075668 [TBL] [Abstract][Full Text] [Related]
44. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416 [TBL] [Abstract][Full Text] [Related]
45. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Shang X; Lin X; Manorek G; Howell SB Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666 [TBL] [Abstract][Full Text] [Related]
46. Role of copper transporters in the uptake and efflux of platinum containing drugs. Safaei R Cancer Lett; 2006 Mar; 234(1):34-9. PubMed ID: 16297532 [TBL] [Abstract][Full Text] [Related]
47. Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. Cui H; Zhang AJ; McKeage MJ; Nott LM; Geraghty D; Guven N; Liu JJ J Inorg Biochem; 2017 Dec; 177():249-258. PubMed ID: 28551160 [TBL] [Abstract][Full Text] [Related]
48. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Holzer AK; Manorek GH; Howell SB Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145 [TBL] [Abstract][Full Text] [Related]
49. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents. Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874 [TBL] [Abstract][Full Text] [Related]
50. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells. Sørensen BH; Dam CS; Stürup S; Lambert IH J Inorg Biochem; 2016 Jul; 160():287-95. PubMed ID: 27112899 [TBL] [Abstract][Full Text] [Related]
51. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer. Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129 [TBL] [Abstract][Full Text] [Related]
52. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. O'Neill CF; Hunakova L; Kelland LR Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899 [TBL] [Abstract][Full Text] [Related]
55. Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B. Tadini-Buoninsegni F; Smeazzetto S IUBMB Life; 2017 Apr; 69(4):218-225. PubMed ID: 28164426 [TBL] [Abstract][Full Text] [Related]
56. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes. Pang SK; So WK; Ho YP; Au-Yeung CF Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313 [TBL] [Abstract][Full Text] [Related]
57. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007 [TBL] [Abstract][Full Text] [Related]
58. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296 [TBL] [Abstract][Full Text] [Related]
59. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs. Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542 [TBL] [Abstract][Full Text] [Related]
60. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Dmitriev OY Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]